*Corresponding Author:
H. Ali
Institute of Pharmaceutical Sciences, Jinnah Sindh Medical University, Karachi-75510, Pakistan
E-mail: humaali80@live.com
Date of Submission 07 March 2017
Date of Revision 16 October 2017
Date of Acceptance 25 May 2018
Indian J Pharm Sci 2018;80(4):610-618  

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms


Drug utilization pattern is premeditated to evaluate appropriateness of drug usage. The current study was performed in a multifaceted tertiary care setting in qualitative and cross sectional manner between January to June 2016. In the present study, the proportion and rate of antibacterial prescribing was found to be comparable to other studies conducted in the recent past. The standard integer of remedial moieties per encounter was also found to be elevated when compared to the analogous investigations carried out in various regions of the world at secondary and tertiary care levels. Patient medical charts were retrieved and retrospectively analyzed to extract relevant data. Demographic variables, gender, age, hospital stay, residing ward were taken into consideration. Whereas other variables for ciprofloxacin, meropenem and amikacin were studied with respect to initial/final diagnoses, administered dose, duration of treatment, dosing interval, frequency of administration, microbial culture/sensitivity test and multiple therapeutic regimen. Outcome measures composed of clinical outcome with respect to therapeutic success or failure. An approximation range of 48-59 % of one additional antibiotic and 30-36 % with two or more drugs was found to be for ciprofloxacin, meropenem and amikacin in selected patient’s cohort during their hospitalization period. Prophylactic, empiric and specific use of ciprofloxacin, meropenem and amikacin were in order of 17-39, 12-22 and 30-43 %. Study results highlighted the need for educational intercessions, development of robust and standard utilization guidelines for antibiotics, which could help overcome irrational practice.


Ciprofloxacin, meropenem, amikacin, drug utilization evaluation, irrational practice

According to the World Health Organization, drug utilization evaluation (DUE), sometimes referred to as drug utilization review (DUR), comprised of continuous, systematic, criteria-based drug assessment to ensure the appropriate use of drugs. It provides formal, structured and continuing review of prescribing pattern, pharmacist dispensing, and medication administration and use by patient. DUE may be performed in prospective, concurrent or retrospective manner. Such studies not only ensure and influence appropriate medication decision making but also improve patient outcomes [1,2]. DUE is a necessary element for periodic examination of drug misuse or unnecessary consumption of medical care and implementation of appropriate actions where required. Like other countries, irrational usage is a common problem attributed by unsafe treatment associated with increased adverse drug reactions and the rapid spread of antibiotic resistant in the community so must be concisely control [3-5]. DUE measures the quality care and sustainability of drug therapy by determining drug usage data in health management. Such analyses are generally conducted to improve the clinical outcomes, prevent misuse of antibiotics, guideline compliance towards medical standards and to avoid drug-drug interactions [6]. Rational utilization guide usually refers to selection of accurate medications, satisfactory dose, extent and effective management. Appropriate drug consumption helps health care practitioners in improving their routine treatment practice [7]. Antibiotics are widely prescribed by the health care professionals in emergency room and about 85 % of these prescriptions are generated by general practitioners. Among different antimicrobial agents, antibiotics are considered as most commonly used and misused among other drugs [8,9]. Various studies have been conducted to explore provision of educational information to manage antibiotic usage. In acute hospitalization, about 20-30 % patients received antibiotics every day. European surveillance of antimicrobial consumption showed 18.53 % share of parenteral gentamicin [10]. A study of hospitalized patients in Ethiopia accounted 25.6 % usage of gentamicin for pneumonia and acute gastroenteritis [11]. Amikacin was first introduced as a broad spectrum aminoglycoside in 1981 to treat various infections caused by Gram-negative bacteria such as septicemia, meningitis, endocarditis, pneumonia and tuberculosis. Drug-induced hepatotoxicity is not usually reported and liver injury was found to be of very rare occurrence. Other common adverse effects included hypersensitivity reactions, nausea/vomiting, vertigo and headache [12]. Poor usage of amikacin may cause harmful effects; the results of a trial indicated only 48 % of patients treated with amikacin were exactly followed treatment guidelines [13]. However, according to a survey, most of the critically ill patients in intensive care unit (ICU) and burns unit of a hospital acknowledged 53.3 % of amikacin drug utilization [14]. Ciprofloxacin, a fluoroquinolone was approved in 1987 to treat a variety of systemic infections. It is effective against lower respiratory tract infections, serious gastrointestinal (GI) infections, soft tissues and bone infections and typhoid [15]. Ciprofloxacin found to be the treatment of first choice (42 %) for urinary tract infections (UTI) in 2005 as compared to (0 %) in 2007 by another trial. The clinical audit must be carried out to evaluate the accuracy of antibiotic consumption according to national guidelines [16]. In contrast, an appropriate DUE of ceftriaxone was higher (65.5 %) in Korean University hospitals for liver toxicity, GI complications and neuropathy [17]. A few cases of ciprofloxacin-induced photosensitivity, hypersensitivity, anaphylaxis, vasculitis and erythema multiform were documented [18]. Previous studies in Nepal and a Canadian province suggested fluoroquinolone as most widely prescribed group of antibacterials over a period of 3 y [19]. A study documented appropriate use of ciprofloxacin against clinical indication among 95 % of patients [20]. Similarly the trend of intravenous ciprofloxacin was higher (67.6 %) in SaudiArabia [21]. In many instances, therapy was initiated with parenteral ciprofloxacin but later switched over to oral fluoroquinolones, one such study declared 26 % of parenteral administration of fluoroquinolones [10]. In an American study, fluoroquinolones were most commonly used by the specialties of family practice, internal medicine and urology. Another research study reported the highest utilization of ciprofloxacin in UTI, acute gastroenteritis and chronic obstructive pulmonary disease [19]. A decline in unjustified usage of ciprofloxacin has been reported from 31 to 13 % [22] and its regular consumption found (28.4 %) for UTI by a survey research [12]. In comparison to least use of gentamicin, approximately 1/3 of antibiotic utilization consists of ciprofloxacin [23]. Further study revealed that only 26 % of patients who received ciprofloxacin were consistent with the indications given in hospital formulary [24]. Meropenem classified as wide ranged antibacterial drug of carbapenem family approved in 1994. It is well tolerated and has good CNS and GI tolerability. The most common adverse events reported for meropenem were diarrhoea, skin rash and nausea/ vomiting [25]. In the US, therapeutic indications of meropenem recommended for skin infection, abdominal infections and meningitis where as other various states suggest its use for pneumonia, complicated UTI and community acquired pneumonia [26]. Furthermore, the findings of a study conducted in Karachi showed drug resistance, increased medical cost and highest adverse reaction as chief consequences related to unnecessary utilization of meropenem in about 43 % of renal insufficient patients [27]. Moreover, the clinical findings in Thailand indicated frequent misuse of meropenem (19.3 %) out of 111 prescriptions along with 39 prescriptions of missed dose adjustment and 12 prescriptions showed inaccurate dose regimen [28]. As antibiotics are frequently recommended in various health care settings for management and treatment of a range of ailments from common to complex situations, irrational and needless utilization of such drugs remains the most prevalent problem in under developed and developing countries. Such practices included inadvertent and excessive exploitation of antibacterial agents, which unfortunately became the major reason for the emergence of drug resistance, the prime obstacle in clinical management of infectious diseases that demands various strategic tools to manage and overcome such problems. Present study is planned to assess the appropriateness of various intravenously administered antibiotics in a tertiary care in-patient setting in Karachi, Pakistan.

Materials and Methods

The current study was carried out in a multifaceted tertiary care setting in Karachi with completely developed medical specialties. The qualitative, cross sectional DUE was performed prospectively by reviewing medical records of 250 patients admitted to various departments or units of tertiary care hospital between the periods of 1 January to 30 June 2016. Prior approval of the presented research work was obtained from Institutional Ethics Committee (0211016ATPHARM). A formal permission was obtained from the hospitals administration. Confidentiality of the record was sustained all the way through the period of the research. All the patient records like demographic, medical and disease profiles were kept fully confidential.

Inclusion and exclusion criteria

Patients prescribed with selected antibiotics like intravenous ciprofloxacin, meropenem and amikacin and those who were admitted to various hospital units such as internal/community medicine, pediatrics, GI, emergency, specialized care unit, infectious disease, surgery, and some others units were qualified the inclusion criteria in the present study. Patients with incomplete medications and or records were excluded.

Study protocol

Using the system of hospital information, the respective record numbers of each patient who received intravenous ciprofloxacin, meropenem and amikacin for the stated period were acquired. For calculation of sample size the guidance of the Joint Commission on the Accreditation of Health Care Organization standard were considered [29]. An average approximation of 1000 cases was recognized with antibiotics on periodical quarterly base from participating hospital. Therefore, 25 % cases (n=250) of total population were selected in current investigation from various units. A semi structured data collection form designed, providing a mixed approach of open- and close-ended questions to obtain the required details of patients’ medical profiles for the continuation of research work in order to produce the data that can be analysed quantitatively for evaluation of drug utilization pattern of specific group of drugs. The questionnaire was pretested to conduct the data collection for better understanding and interpretation of appropriate findings of the relevant parameters of study. Data collection form included the demographic and diagnostic details of hospitalized patients, antibiotic utilization data from various healthcare units, estimation of dosing, frequency, interval, adequacy of antibiotic administration and treatment duration as well as the determination of clinical outcomes associated with therapy. The patient’s medical charts were retrieved and retrospectively analysed for extraction of relevant data. For assessment of demographic variables, gender, age, hospital stay, residing ward were taken into consideration. Whereas prescribing variables for ciprofloxacin, meropenem and amikacin were studied with respect to initial/final diagnoses, administered dose, duration of treatment, dosing interval, frequency of administration, microbial culture/sensitivity test and multiple therapeutic regimen.

Outcome measures were composed of clinical outcome with respect to therapy success or failure. Selected prescriptions of ciprofloxacin, meropenem and amikacin were also classified into subsequent categories of prophylactic, specific, empiric with respect to their rationale for utilization. Appropriate and rationale use of antibiotic was assessed by considering the quality criteria presented by Gyssens et al. [30] and the guidelines presented by American Hospital Formulary Systems for optimal antibiotic therapy. The subsequent taxonomy was applied such as suitability of prescription, inaptness attributable to objectionable dose, route and administration intervals, incongruity owing to the extent or ineffective drug inclusion, inappropriate indication and report of inadequate utilization. The required information was recorded in a pre-constructed data collection form by trained pharmacists. Validation of data collection format for accepted consistency and reliability was carried out by measuring the coefficient of spearman correlation and Cronbach’s α values (P=0.908 and α=0.899). In case of any query and unclear scenario during the data collection and interpretation phase, a panel of clinical pharmacist, physician and pharmacologist was conferred to reach the suitable consensus.

Statistical analysis

Data was descriptively analysed using software SPSS (version, 20). Qualitative data was presented in term of frequency and percentages whereas quantitative expressions were calculated with mean and standard deviations. Furthermore, in this study, antibiotic rationalization odds ratios (ORs) were calculated using confidence intervals (CI) 95 % with a level of significance at P<0.05 level. In this regard, logistic model of regression was applied to observe the relationship among antibiotics and appropriate utilization.

Results and Discussion

The current investigation was carried out to evaluate the utilization pattern of intravenous ciprofloxacin, meropenem and amikacin in various units of tertiary care setting in Karachi, Pakistan. These agents were selected due to the broad spectrum activity against multiple strains of pathogens and accounted for the consumption of a considerable fraction of most hospitals’ outlay with respect to these antibacterial agents. On the basis of preliminary evaluation a significantly high number of patients were identified with ciprofloxacin, meropenem and considerably low with amikacin therapies. Final cohort was composed of 250 patients with n=100 each for ciprofloxacin and meropenem receivers and n=50 for amikacin group. Literature was evaluated to retrieve the DUE studies of selected drugs, but very small amount of such studies were reported by other investigators. Details related to the demographic variables like age, gender of patients and antibiotics distribution and utilization amongst diverse hospital units/ward were summarized in Table 1. Mean age of study respondents were in order of 36.64±17.16, 42.88±16.89 and 33.46±18.45 for ciprofloxacin, meropenem and amikacin, respectively. Whereas, higher usage of ciprofloxacin was observed in gastroenterology department (25 %), while meropenem and amikacin were substantially prescribed for specialized care unit (27 %) and pediatrics ward (28 %), respectively. During the study appropriateness of intravenous (IV) ciprofloxacin, meropenem and amikacin therapies in patient’s cohorts were estimated and presented in Table 2. Amendments in diagnostic profiles for respective drugs in selected patient’s cohort were also noted and mentioned in Table 3. Similarly antibiotics administered before, concurrent and after ciprofloxacin, meropenem and amikacin therapies were observed to determine the polypharmacy practices and appropriateness of prescriptions (Table 4). Frequency of prescriptions with respect to sole antibiotic or combination was also evaluated (Figure 1). Average clinical outcomes of ciprofloxacin, meropenem and amikacin were calculated as therapeutic success or failure indicator (Table 5, Figure 2). Statistical presentation of drug utilization data with respect to OR has also been elucidated with respect to reasons of inappropriateness in therapy (Figure 3) and appropriateness of treatment in specific groups of antibiotics (Table 6). Whereas, utilization pattern of ciprofloxacin, meropenem and amikacin on the basis of indication and prophylactic, empiric and specific use was also determined in current investigation (Figure 4).

Demographic details of patients Ciprofloxacin IV
(n=100) %
(n=100) %
(n=50) %
Male 63 (63 %) 48 (48 %) 31 (62 %)
Female 37 (37 %) 52 (52 %) 19 (38 %)
Total 100 100 50
Age (Years)
2-15 (years) 12 (12 %) 8 (9 %) 17 (17 %)
16- 30 (years) 19 (19 %) 14 (14 %) 26 (14 %)
30-45 (years) 28 (28 %) 31 (31 %) 34 (31 %)
45-60 and above 41(41 %) 47 (47 %) 23 (47 %)
Mean age (years) 36.64±17.16 42.88±16.89 33.46±18.45
Wards/healthcare units (n=100) p (n=100) p (n=100) p
Internal/community medicine 17 (0.17) 19 (0.19) 10 (0.20)
Pediatrics 8 (0.08) 5 (0.05) 14 (0.28)
Gastrointestinal 25 (0.25) 15 (0.15) 7 (0.14)
Emergency 5 (0.05) 6 (0.06) 5 (0.10)
Specialized care unit 7 (0.07) 27 (0.27) 1 (0.02)
Surgical unit 12 (0.18) 8 (0.08) 3 (0.06)
Infectious disease 18 (0.25) 11 (0.11) 8 (0.16)
Others 8 (0.12) 9 (0.09) 2 (0.04)

Table 1: Patients demographic features and utilization details of related antibiotics in various wards/hospital units

Parameters Ciprofloxacin IV (n, %) Meropenem (n, %) Amikacin (n, %)
Dose administered 90 (90 %) 81 (81 %) 42 (84 %)
Dosing interval 84 (84 %) 98 (98 %) 39 (78 %)
Treatment period/extent 65 (65 %) 78 (78 %) 45 (90 %)
Frequency of administration 83 (83 %) 92 (92 %) 41 (82 %)

Table 2: Estimation of appropriateness of intravenous (iv) ciprofloxacin, meropenem and amikacin therapies in patient’s cohorts

Meropenem Ciprofloxacin Amikacin
Final diagnoses Initial diagnoses Final diagnoses Initial diagnoses Final diagnoses Initial diagnoses
Tuberculosis Chronic obstructive pulmonary disease (COPD) Urinary tract infection (UTI) Fever, abdominal pain Foreign object Pneumonia
Pneumonia Pneumonia Bowel obstruction Constipation, pain UTI Fever, abdominal cramps
Pneumonia Chest infection Lower respiratory tract infection (LRTI) Abdominal pain and congestion Pneumonia COPD
Pneumonia COPD Peptic ulcer disease Fever, abdominal pain Ascites Dyspnea
Abdominal Ascites Fever, vomiting Bowel syndrome Fever, abdominal pain    
Pneumonia Chest congestion Appendicitis Fever and abdominal pain Foreign object Pneumonia
Meningitis Loss of consciousness Encephalopathy Dyspnea Bronchitis Fever, congestion
Meningitis High grade fever Pulmonary edema Respiratory distress Tuberculosis Dyspnea
Tuberculosis Pneumonia UTI Vaginitis, fever Hospital acquired pneumonia Loss of consciousness/ fever
Ascites Acute abdominal pain Vaginal infection UTI Non-tubercular mycobacterial infection Pneumonia
Meningitis Loss of consciousness UTI Fever and acidosis UTI Lower abdominal pain
Pneumonia Fever and vertigo Peptic ulcer disease Fever Neutropenia Fever
Acute Renal Failure Loss of consciousness and edema Bowel obstruction Constipation Hospital acquired infection Fever, COPD

Table 3: Amendments in diagnostic profiles for respective drugs in selected patient’s cohort

Meropenem Ciprofloxacin Amikacin
Prior Concurrent Subsequent Prior Concurrent Subsequent Prior Concurrent Subsequent
levofloxacin Clindamycin Ceftriaxone cefixime - Ceftriaxone Moxifloxacin - Cefixime
moxifloxacin amikacin Ceftriaxone levofloxacin - Ceftriaxone levofloxacin - Ceftriaxone
Ceftriaxone - cefixime moxifloxacin amikacin - Ceftriaxone Metronidazole Azithromycin
sulbactam - Ceftriaxone levofloxacin - Ceftriaxone Augmentin Piperacillin/ Tazobactam -
Ceftriaxone Colistin Piperacillin/ Tazobactam   Ceftriaxone - Ceftriaxone/
Piperacillin/ Tazobactam Sulbactam Ceftriaxone
Ceftriaxone Ceftriaxone/
- Ceftriaxone/ Clindamycin Cefotaxime/Metronidazole Metronidazole Augmentin Piperacillin/ Tazobactam ceftazidime
Piperacillin/ Tazobactam - Ceftriaxone Ceftriaxone/ Azithromycin amikacin Augmentin Ceftriaxone Piperacillin/ Tazobactam Augmentin
moxifloxacin Amikacin cefixime Ceftriaxone Cefotaxime/ Cloxacillin Ceftriaxone/ Metronidazole Sulbactam - Augmentin
Piperacillin/ Tazobactam   Ceftriaxone cefixime Ceftriaxone/
Metronidazole/ Cefotaxime
Ceftriaxone /
Metronidazole Piperacillin/ Tazobactam - Ceftriaxone

Table 4: Antibiotics administered before, concurrent and after ciprofloxacin, meropenem and amikacin


Figure 1: Frequency of prescribed drugs with meropenem, ciprofloxacin and amikacin
image Meropenem; image ciprofloxacin; image amikacin

Response Frequencies Ciprofloxacin IV
(n=100) p
(n=100) p
(n=50) p
Therapeutic effectiveness 89 (0.89) 85 (0.84) 43 (0.86)
Therapeutic failure 9 (0.09) 8 (0.08) 6 (0.12)
Mortality 2 (0.02) 7 (0.07) 1 (0.02)

Table 5: Average clinical outcomes of ciprofloxacin, meropenem and amikacin


Figure 2: Clinical response of ciprofloxacin, meropenem and amikacin.
image Therapeutic effectiveness; image therapeutic failure; image mortality


Figure 3: Categorical presentation of inappropriate use of antibiotics
image Inappropriate indication (27.18 %); image inadequate spectrum (18.12 %); image incorrect dose (36.25 %); image wrong duration (24.16 %); image wrong dosage interval (30.20 %); image inapt therapy (13.9 %)


Figure 4: Utilization pattern of ciprofloxacin, meropenem and amikacin on the basis of indication
image Meropenem; image ciprofloxacin; image amikacin

Rationale For Inaptness Frequency of Inappropriate outcome (n, %) P-value OR (CI: 95 %)
Causes for inappropriateness of antibiotic therapies
Inapt therapy 13 (5.2 %) ˂0.0001 0.149 (0.078-0.284)
Inappropriate indication 27 (10.8 %) 0.0002 0.369 (0.219-0.622)
Inadequate spectrum 18(7.2 %) ˂0.0001 0.219 (0.122-0.392)
Incorrect dose 36(14.4 %) 0.0223 0.562 (0.343-0.921)
Wrong duration 24 (9.6 %) ˂0.0001 0.315 (0.184-0.539)
Reprehensible dosage interval 30 (12 %) 0.0011 0.428 (0.257-0.713)
Appropriateness of treatment in specific groups of antibiotics
Ciprofloxacin (IV) 87 (87 %) ˂0.0001 0.149 (0.078-0.284)
Meropenem (IV) 88 (88 %) ˂0.0001 0.136 (0.070-0.264)
Amikacin (IV) 41(82 %) ˂0.0001 0.219 (0.122-0.392)

Table 6: Statistical presentation of drug utilization data with respect to odd ratio (OR)

Irrational, over and misuse of antibiotics arises as global concern in recent days in both hospital and community settings and lead to adverse events including antimicrobial resistance, associated health problems, amplified hospitalization stay and cost [31]. In developing countries where antibiotic-management systems hardly exist, contrasting situations become more complex, which provide the undeniable evidence of the need for more rational use of antibiotics [32,33]. Prescribing practices are the main manifestation of health care professional abilities to assess best drug option for patients. Similarly, prescribing pattern is a component of medical appraisal, seek monitoring and recommend modifications in prescribing trend to make it rational and effective [34]. One of the most important points in health care systems is to evaluate the appropriateness of medication use. Hence, DUE or DUR studies are designed to evaluate and improve the prescribing, administration and the rational use of medications [35]. Current study exposed that maximum number of patients were prescribed an antibiotic at the time of admission. On the whole, 250 medical records were reviewed containing three antibiotics exclusively, ciprofloxacin, meropenem and amikacin administered IV. Though, few medical records were not appropriately detailed to present adequate information for the estimation of the actual pattern of the antibiotics utilization and respective quality valuation. However, higher OR values were observed with incorrect dose i.e., 0.562 (0.343-0.921), followed by inappropriate drug interval 0.428 (0.257-0.713). While lowest values of OR were observed with inapt therapies 0.149 (0.078-0.284) and inadequate spectrum levels 0.219 (0.122-0.392) at 95 % confidence interval (CI; Table 6). Estimation of appropriateness of such treatments in patient’s cohorts described the same diagnosis supported by various evaluations. Amongst the various antimicrobial cohorts, meropenem and ciprofloxacin were utilized in least inappropriate manner (OR; 0.136 (0.070-0.264); 0.149 (0.078- 0.284); Table 6). Furthermore frequency of antibiotic prescription along with single or multiple units was also determined and presented in Figure 1. One of the retrospective studies indicated 22 prescriptions of ciprofloxacin in patients who underwent surgery [36] in contrast to 12 prescriptions in this study. According to another trial, meropenem prescribed 22 % in ICU patients and in 35 % cases of pneumonia [37]. Such results were almost similar to those of this study given in Table 1 for meropenem. Another study reported that combination therapy of meropenem with levofloxacin gave considerable better resistance suppression than did either monotherapy particularly in ventilatorassociated pneumonia [38]. Although the principles of antibiotic prescriptions have been well-established internationally for many years but inappropriate use is still common particularly in developing countries [39]. Several investigations revealed remarkable differences in the patterns of unsuitable prescribing, wrong choice, and improper use of antibiotics in different hospital units [40,41]. In the present investigation, inappropriate prescriptions of antibiotics were 27.18 % against the indication, wrong duration 24.16 and 18.12 % inadequate spectrum were the frequent errors. However, these findings reported high among hospitalized patients and need crucial focus on health management. Furthermore, clinical response of meropenem might lead to mortality compared to the use of ciprofloxacin and amikacin mention in Figure 2. A research showed that though meropenem was well tolerated by offspring, adults and has a satisfactory safety report, meropenem dosing strategies and optimization of outcomes were under examination [42]. Non-randomized studies suggested that combination antibiotic treatment might present a relative advantage over monotherapy in view of mortality of seriously ill patients [43]. Mohr investigated the range of hospital stay with meropenem from 3 to 14 d [42]. Furthermore, various researchers proved that effective combination of ciprofloxacin with metronidazole and meropenem itself found to decrease the length of hospitalization and treatment duration for complicated abdominal infections [42-44]. The results of our study underline numerous areas that necessitate upgrading. Most importantly, there is a need to devise stern antibiotic restriction strategy and apply protocols for antibiotic usage in order to rationalize the prudent use of these drugs. Studies have revealed that the implementation of judicious antibiotic principles have had a noteworthy optimistic economic advantage and superior quality of care delivered to patients. Baseline data on the incidence of antibiotic use considered as the first step in encouraging drug monitoring and quality improvement. Next step need to evaluate adherence of prescribing health care providers towards clinical criteria for specific diagnosis.

The present study showed therapeutic effectiveness of parenteral administration of ciprofloxacin and meropenem in majority of cases as compared to amikacin. But in contrast to ciprofloxacin, mortality rate was greater with meropenem. So quality of life can be enhanced by considering the standards of medical treatment at all levels of the health care system in order to improve health outcomes and to minimize the death rate. There is a substantial capacity for improvement in the DUE model. These findings suggest the need for implementing antimicrobial treatment guidelines. An antimicrobial stewardship program would offer the most comprehensive key for correct use of antimicrobials. Furthermore with the increasing interest in patient safety with respect to disease management and cost of care, factual estimates of drug utilization are of growing importance. It is essential to take action to recover drug utilization practice in order to minimize unnecessary usage of antibiotic thus augment the rational use.

Financial support and sponsorship


Conflicts of interest

There are no conflicts of interest.